600513.SH
联环药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 15.64
−6.01%Year over year
Reported trailing growth
- Revenue
- +28.1%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -13.3%
- Operating cash flow
- -65.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +11.5%
- EBITDA
- -27.3%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -64.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026